CUPR

F-1 - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

20-F/A - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("CUPR" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that an indirectly wholly-owned subsidiary of the Company, Cuprina Pte. Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MEDIFLY Maggots™, its medical-grade Lucilia cuprina larvae used in maggot debridement therapy (MDT). To the Company's knowledge, MEDIFLY Maggots™ is the first maggot debridement product to receive U.S. FDA 510(k) clearance using the Lucilia cuprina species.

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that on June 11, 2026 it has regained compliance with the Nasdaq Capital Markets Listing Requirements. As previously disclosed on May 29, 2026, the Company received a Staff Delisting Determinations Letter (the "Staff Determination") indicating that the Company's securities had closed below $1.00 per share for 30 consecutive business days, failing to meet the minimum bid price requirement under Listing Rule 555

SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it completed a reverse stock split on May 27, 2026, and requested  a hearing before the Nasdaq Hearings Panel (the "Panel"), in response to a staff determination letter (the "Letter") received on May 27, 2026, from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq"). The Letter notified the Company that, due to the Company's failure to regain compliance with a minim

SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares ("Class A Ordinary Shares") and Class B ordinary shares ("Class B Ordinary Shares") (the "Share Consolidation"), effective on or around May 27, 2026. Beginning with the opening of trading on or around May 27, 2026, the Company's Class A Ordinary Shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capi

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

6-K/A - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

20-F - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Regulatory Milestone in Saudi Arabia Cuprina's 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority (SFDA) for MEDIFLY, the Company's medical-grade maggot debridemen

SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced its financial results for the six months ended June 30, 2025. "Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant advances in both diversifying our product and technology portfolio and expanding our geographic footprint," said Cuprina Chief Executive Officer, Mr. David Quek Yong Qi. Diversification

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina's closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), th